nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—rectum cancer	0.822	1	CtDrD
Sorafenib—KIT—myenteric nerve plexus—rectum cancer	0.00413	0.0433	CbGeAlD
Sorafenib—PDGFRA—penis—rectum cancer	0.00293	0.0307	CbGeAlD
Sorafenib—RET—autonomic nervous system—rectum cancer	0.0029	0.0304	CbGeAlD
Sorafenib—CDKL3—female reproductive system—rectum cancer	0.00167	0.0175	CbGeAlD
Sorafenib—CDKL2—female reproductive system—rectum cancer	0.00153	0.016	CbGeAlD
Sorafenib—MAPK15—female reproductive system—rectum cancer	0.00138	0.0144	CbGeAlD
Sorafenib—ZAK—seminal vesicle—rectum cancer	0.00107	0.0113	CbGeAlD
Sorafenib—CDK7—renal system—rectum cancer	0.001	0.0105	CbGeAlD
Sorafenib—TAOK2—urethra—rectum cancer	0.000976	0.0102	CbGeAlD
Sorafenib—HIPK4—female reproductive system—rectum cancer	0.000925	0.00971	CbGeAlD
Sorafenib—EPHX2—seminal vesicle—rectum cancer	0.0009	0.00945	CbGeAlD
Sorafenib—TIE1—epithelium—rectum cancer	0.000854	0.00896	CbGeAlD
Sorafenib—ZAK—urethra—rectum cancer	0.000851	0.00893	CbGeAlD
Sorafenib—HIPK3—renal system—rectum cancer	0.000847	0.00889	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—rectum cancer	0.000823	0.00863	CbGeAlD
Sorafenib—MAPK11—female reproductive system—rectum cancer	0.000816	0.00856	CbGeAlD
Sorafenib—ZAK—mammalian vulva—rectum cancer	0.00081	0.0085	CbGeAlD
Sorafenib—CDK7—female reproductive system—rectum cancer	0.000802	0.00842	CbGeAlD
Sorafenib—AURKC—female reproductive system—rectum cancer	0.00079	0.00829	CbGeAlD
Sorafenib—TIE1—urethra—rectum cancer	0.000778	0.00817	CbGeAlD
Sorafenib—MAP3K7—seminal vesicle—rectum cancer	0.000758	0.00796	CbGeAlD
Sorafenib—MKNK2—seminal vesicle—rectum cancer	0.000735	0.00772	CbGeAlD
Sorafenib—EPHA6—female reproductive system—rectum cancer	0.000731	0.00768	CbGeAlD
Sorafenib—TAOK2—vagina—rectum cancer	0.00072	0.00756	CbGeAlD
Sorafenib—EPHX2—urethra—rectum cancer	0.000713	0.00748	CbGeAlD
Sorafenib—FLT4—epithelium—rectum cancer	0.000705	0.0074	CbGeAlD
Sorafenib—ZAK—female reproductive system—rectum cancer	0.000693	0.00728	CbGeAlD
Sorafenib—HIPK3—female reproductive system—rectum cancer	0.000679	0.00712	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—rectum cancer	0.000679	0.00712	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—rectum cancer	0.000665	0.00698	CbGeAlD
Sorafenib—RALBP1—seminal vesicle—rectum cancer	0.000664	0.00697	CbGeAlD
Sorafenib—UGT1A9—renal system—rectum cancer	0.000664	0.00697	CbGeAlD
Sorafenib—MKNK2—epithelium—rectum cancer	0.000639	0.0067	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—rectum cancer	0.000635	0.00666	CbGeAlD
Sorafenib—TIE1—female reproductive system—rectum cancer	0.000634	0.00666	CbGeAlD
Sorafenib—FGFR1—urethra—rectum cancer	0.000634	0.00666	CbGeAlD
Sorafenib—FLT1—seminal vesicle—rectum cancer	0.000631	0.00663	CbGeAlD
Sorafenib—RAF1—seminal vesicle—rectum cancer	0.000628	0.00659	CbGeAlD
Sorafenib—ZAK—vagina—rectum cancer	0.000627	0.00658	CbGeAlD
Sorafenib—EPHB6—seminal vesicle—rectum cancer	0.000624	0.00655	CbGeAlD
Sorafenib—RET—epithelium—rectum cancer	0.000623	0.00654	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—rectum cancer	0.000615	0.00646	CbGeAlD
Sorafenib—HIPK3—vagina—rectum cancer	0.000614	0.00644	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—rectum cancer	0.000604	0.00634	CbGeAlD
Sorafenib—MAP3K7—urethra—rectum cancer	0.0006	0.0063	CbGeAlD
Sorafenib—MKNK2—renal system—rectum cancer	0.000592	0.00622	CbGeAlD
Sorafenib—MKNK2—urethra—rectum cancer	0.000582	0.00611	CbGeAlD
Sorafenib—RET—renal system—rectum cancer	0.000578	0.00606	CbGeAlD
Sorafenib—FLT3—female reproductive system—rectum cancer	0.000577	0.00606	CbGeAlD
Sorafenib—MKNK1—urethra—rectum cancer	0.000574	0.00603	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—rectum cancer	0.000572	0.006	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—rectum cancer	0.000556	0.00583	CbGeAlD
Sorafenib—MKNK2—mammalian vulva—rectum cancer	0.000554	0.00581	CbGeAlD
Sorafenib—BRAF—vagina—rectum cancer	0.00055	0.00577	CbGeAlD
Sorafenib—FLT1—epithelium—rectum cancer	0.000549	0.00576	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—rectum cancer	0.000547	0.00574	CbGeAlD
Sorafenib—RAF1—epithelium—rectum cancer	0.000545	0.00572	CbGeAlD
Sorafenib—RALBP1—renal system—rectum cancer	0.000535	0.00561	CbGeAlD
Sorafenib—MAP2K5—seminal vesicle—rectum cancer	0.000534	0.0056	CbGeAlD
Sorafenib—KDR—seminal vesicle—rectum cancer	0.000534	0.0056	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—rectum cancer	0.000529	0.00555	CbGeAlD
Sorafenib—EPHX2—vagina—rectum cancer	0.000526	0.00552	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—rectum cancer	0.000525	0.00552	CbGeAlD
Sorafenib—RALBP1—urethra—rectum cancer	0.000525	0.00552	CbGeAlD
Sorafenib—FLT4—female reproductive system—rectum cancer	0.000524	0.0055	CbGeAlD
Sorafenib—CSF1R—seminal vesicle—rectum cancer	0.000521	0.00547	CbGeAlD
Sorafenib—FLT1—renal system—rectum cancer	0.000509	0.00534	CbGeAlD
Sorafenib—RAF1—renal system—rectum cancer	0.000506	0.00531	CbGeAlD
Sorafenib—RALBP1—mammalian vulva—rectum cancer	0.0005	0.00525	CbGeAlD
Sorafenib—FLT1—urethra—rectum cancer	0.0005	0.00525	CbGeAlD
Sorafenib—RAF1—urethra—rectum cancer	0.000497	0.00522	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—rectum cancer	0.000495	0.0052	CbGeAlD
Sorafenib—EPHB6—urethra—rectum cancer	0.000494	0.00519	CbGeAlD
Sorafenib—STK10—renal system—rectum cancer	0.000482	0.00506	CbGeAlD
Sorafenib—MAPK11—lymph node—rectum cancer	0.000477	0.00501	CbGeAlD
Sorafenib—PDGFRA—renal system—rectum cancer	0.000477	0.005	CbGeAlD
Sorafenib—FLT1—mammalian vulva—rectum cancer	0.000476	0.00499	CbGeAlD
Sorafenib—MKNK2—female reproductive system—rectum cancer	0.000474	0.00498	CbGeAlD
Sorafenib—RAF1—mammalian vulva—rectum cancer	0.000473	0.00497	CbGeAlD
Sorafenib—KIT—seminal vesicle—rectum cancer	0.000473	0.00496	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—rectum cancer	0.00047	0.00494	CbGeAlD
Sorafenib—CDK7—lymph node—rectum cancer	0.000469	0.00493	CbGeAlD
Sorafenib—MKNK1—female reproductive system—rectum cancer	0.000468	0.00492	CbGeAlD
Sorafenib—FGFR1—vagina—rectum cancer	0.000468	0.00491	CbGeAlD
Sorafenib—TAOK2—lymph node—rectum cancer	0.000466	0.00489	CbGeAlD
Sorafenib—KDR—epithelium—rectum cancer	0.000464	0.00487	CbGeAlD
Sorafenib—AURKC—lymph node—rectum cancer	0.000462	0.00485	CbGeAlD
Sorafenib—PDGFRB—seminal vesicle—rectum cancer	0.000462	0.00485	CbGeAlD
Sorafenib—UGT1A1—renal system—rectum cancer	0.000455	0.00477	CbGeAlD
Sorafenib—STK10—mammalian vulva—rectum cancer	0.00045	0.00473	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—rectum cancer	0.000447	0.00469	CbGeAlD
Sorafenib—MAP3K7—vagina—rectum cancer	0.000443	0.00465	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—rectum cancer	0.000436	0.00458	CbGeAlD
Sorafenib—KDR—renal system—rectum cancer	0.00043	0.00451	CbGeAlD
Sorafenib—MKNK2—vagina—rectum cancer	0.000429	0.0045	CbGeAlD
Sorafenib—RALBP1—female reproductive system—rectum cancer	0.000428	0.0045	CbGeAlD
Sorafenib—MKNK1—vagina—rectum cancer	0.000424	0.00445	CbGeAlD
Sorafenib—KDR—urethra—rectum cancer	0.000422	0.00443	CbGeAlD
Sorafenib—MAP2K5—urethra—rectum cancer	0.000422	0.00443	CbGeAlD
Sorafenib—CSF1R—urethra—rectum cancer	0.000412	0.00433	CbGeAlD
Sorafenib—KIT—epithelium—rectum cancer	0.000411	0.00431	CbGeAlD
Sorafenib—FLT1—female reproductive system—rectum cancer	0.000407	0.00428	CbGeAlD
Sorafenib—ZAK—lymph node—rectum cancer	0.000406	0.00426	CbGeAlD
Sorafenib—RAF1—female reproductive system—rectum cancer	0.000405	0.00425	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—rectum cancer	0.000402	0.00422	CbGeAlD
Sorafenib—KDR—mammalian vulva—rectum cancer	0.000402	0.00422	CbGeAlD
Sorafenib—PDGFRB—epithelium—rectum cancer	0.000401	0.00421	CbGeAlD
Sorafenib—HIPK3—lymph node—rectum cancer	0.000397	0.00417	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—rectum cancer	0.000396	0.00416	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—rectum cancer	0.000393	0.00412	CbGeAlD
Sorafenib—RALBP1—vagina—rectum cancer	0.000387	0.00407	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—rectum cancer	0.000387	0.00406	CbGeAlD
Sorafenib—STK10—female reproductive system—rectum cancer	0.000386	0.00405	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—rectum cancer	0.000382	0.00401	CbGeAlD
Sorafenib—KIT—renal system—rectum cancer	0.000381	0.004	CbGeAlD
Sorafenib—KIT—urethra—rectum cancer	0.000374	0.00393	CbGeAlD
Sorafenib—PDGFRB—renal system—rectum cancer	0.000372	0.00391	CbGeAlD
Sorafenib—TIE1—lymph node—rectum cancer	0.000371	0.00389	CbGeAlD
Sorafenib—FLT1—vagina—rectum cancer	0.000369	0.00387	CbGeAlD
Sorafenib—RAF1—vagina—rectum cancer	0.000366	0.00385	CbGeAlD
Sorafenib—PDGFRB—urethra—rectum cancer	0.000366	0.00384	CbGeAlD
Sorafenib—EPHB6—vagina—rectum cancer	0.000364	0.00382	CbGeAlD
Sorafenib—KIT—mammalian vulva—rectum cancer	0.000356	0.00374	CbGeAlD
Sorafenib—BRAF—lymph node—rectum cancer	0.000356	0.00373	CbGeAlD
Sorafenib—STK10—vagina—rectum cancer	0.000349	0.00366	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—rectum cancer	0.000348	0.00365	CbGeAlD
Sorafenib—PDGFRA—vagina—rectum cancer	0.000345	0.00362	CbGeAlD
Sorafenib—KDR—female reproductive system—rectum cancer	0.000344	0.00362	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—rectum cancer	0.000344	0.00362	CbGeAlD
Sorafenib—EPHX2—lymph node—rectum cancer	0.00034	0.00357	CbGeAlD
Sorafenib—FLT3—lymph node—rectum cancer	0.000338	0.00354	CbGeAlD
Sorafenib—CSF1R—female reproductive system—rectum cancer	0.000336	0.00353	CbGeAlD
Sorafenib—KDR—vagina—rectum cancer	0.000312	0.00327	CbGeAlD
Sorafenib—MAP2K5—vagina—rectum cancer	0.000312	0.00327	CbGeAlD
Sorafenib—FLT4—lymph node—rectum cancer	0.000307	0.00322	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—rectum cancer	0.000306	0.00321	CbGeAlD
Sorafenib—KIT—female reproductive system—rectum cancer	0.000305	0.0032	CbGeAlD
Sorafenib—CSF1R—vagina—rectum cancer	0.000304	0.00319	CbGeAlD
Sorafenib—FGFR1—lymph node—rectum cancer	0.000302	0.00317	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—rectum cancer	0.000298	0.00313	CbGeAlD
Sorafenib—ABCC4—renal system—rectum cancer	0.000296	0.00311	CbGeAlD
Sorafenib—ABCC2—renal system—rectum cancer	0.000287	0.00301	CbGeAlD
Sorafenib—MAP3K7—lymph node—rectum cancer	0.000286	0.00301	CbGeAlD
Sorafenib—MKNK2—lymph node—rectum cancer	0.000277	0.00291	CbGeAlD
Sorafenib—KIT—vagina—rectum cancer	0.000276	0.0029	CbGeAlD
Sorafenib—MKNK1—lymph node—rectum cancer	0.000274	0.00288	CbGeAlD
Sorafenib—RET—lymph node—rectum cancer	0.000271	0.00284	CbGeAlD
Sorafenib—PDGFRB—vagina—rectum cancer	0.00027	0.00283	CbGeAlD
Sorafenib—ABCG2—seminal vesicle—rectum cancer	0.00026	0.00273	CbGeAlD
Sorafenib—HTR2C—female reproductive system—rectum cancer	0.000251	0.00264	CbGeAlD
Sorafenib—RALBP1—lymph node—rectum cancer	0.000251	0.00263	CbGeAlD
Sorafenib—FLT1—lymph node—rectum cancer	0.000238	0.0025	CbGeAlD
Sorafenib—ABCC4—female reproductive system—rectum cancer	0.000237	0.00249	CbGeAlD
Sorafenib—RAF1—lymph node—rectum cancer	0.000237	0.00249	CbGeAlD
Sorafenib—HTR2B—female reproductive system—rectum cancer	0.000236	0.00248	CbGeAlD
Sorafenib—EPHB6—lymph node—rectum cancer	0.000236	0.00247	CbGeAlD
Sorafenib—ABCC2—female reproductive system—rectum cancer	0.00023	0.00241	CbGeAlD
Sorafenib—STK10—lymph node—rectum cancer	0.000226	0.00237	CbGeAlD
Sorafenib—PDGFRA—lymph node—rectum cancer	0.000223	0.00234	CbGeAlD
Sorafenib—CYP2C8—renal system—rectum cancer	0.000215	0.00226	CbGeAlD
Sorafenib—HTR2B—vagina—rectum cancer	0.000214	0.00224	CbGeAlD
Sorafenib—ABCG2—urethra—rectum cancer	0.000206	0.00216	CbGeAlD
Sorafenib—MAP2K5—lymph node—rectum cancer	0.000201	0.00212	CbGeAlD
Sorafenib—KDR—lymph node—rectum cancer	0.000201	0.00212	CbGeAlD
Sorafenib—CYP1A2—renal system—rectum cancer	0.000201	0.00211	CbGeAlD
Sorafenib—CSF1R—lymph node—rectum cancer	0.000197	0.00206	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—rectum cancer	0.000196	0.00205	CbGeAlD
Sorafenib—CYP3A5—renal system—rectum cancer	0.000194	0.00204	CbGeAlD
Sorafenib—CYP2B6—renal system—rectum cancer	0.000193	0.00203	CbGeAlD
Sorafenib—CYP2C19—vagina—rectum cancer	0.000179	0.00187	CbGeAlD
Sorafenib—KIT—lymph node—rectum cancer	0.000179	0.00187	CbGeAlD
Sorafenib—PDGFRB—lymph node—rectum cancer	0.000174	0.00183	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—rectum cancer	0.000172	0.00181	CbGeAlD
Sorafenib—CYP2C8—vagina—rectum cancer	0.000156	0.00164	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—rectum cancer	0.000155	0.00162	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—rectum cancer	0.000153	0.00161	CbGeAlD
Sorafenib—ABCG2—vagina—rectum cancer	0.000152	0.00159	CbGeAlD
Sorafenib—CYP3A4—renal system—rectum cancer	0.000146	0.00153	CbGeAlD
Sorafenib—CYP2D6—renal system—rectum cancer	0.000143	0.00151	CbGeAlD
Sorafenib—CYP3A5—vagina—rectum cancer	0.000141	0.00148	CbGeAlD
Sorafenib—CYP2B6—vagina—rectum cancer	0.00014	0.00147	CbGeAlD
Sorafenib—ABCC4—lymph node—rectum cancer	0.000139	0.00146	CbGeAlD
Sorafenib—HTR2B—lymph node—rectum cancer	0.000138	0.00145	CbGeAlD
Sorafenib—ABCC2—lymph node—rectum cancer	0.000134	0.00141	CbGeAlD
Sorafenib—ABCB1—seminal vesicle—rectum cancer	0.000128	0.00134	CbGeAlD
Sorafenib—CYP3A4—female reproductive system—rectum cancer	0.000117	0.00123	CbGeAlD
Sorafenib—CYP2D6—female reproductive system—rectum cancer	0.000115	0.00121	CbGeAlD
Sorafenib—ABCB1—epithelium—rectum cancer	0.000111	0.00117	CbGeAlD
Sorafenib—ABCB1—renal system—rectum cancer	0.000103	0.00108	CbGeAlD
Sorafenib—ABCB1—urethra—rectum cancer	0.000101	0.00106	CbGeAlD
Sorafenib—ABCG2—lymph node—rectum cancer	9.8e-05	0.00103	CbGeAlD
Sorafenib—ABCB1—mammalian vulva—rectum cancer	9.65e-05	0.00101	CbGeAlD
Sorafenib—ABCB1—female reproductive system—rectum cancer	8.26e-05	0.000867	CbGeAlD
Sorafenib—ABCB1—vagina—rectum cancer	7.47e-05	0.000784	CbGeAlD
Sorafenib—ABCB1—lymph node—rectum cancer	4.83e-05	0.000507	CbGeAlD
Sorafenib—PDGFRB—Signaling by PDGF—HRAS—rectum cancer	2.78e-05	0.000335	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—TP53—rectum cancer	2.76e-05	0.000333	CbGpPWpGaD
Sorafenib—RAF1—Insulin Signaling—HRAS—rectum cancer	2.75e-05	0.000331	CbGpPWpGaD
Sorafenib—RAF1—Downstream signal transduction—HRAS—rectum cancer	2.74e-05	0.00033	CbGpPWpGaD
Sorafenib—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	2.73e-05	0.000329	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR—HRAS—rectum cancer	2.72e-05	0.000328	CbGpPWpGaD
Sorafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	2.72e-05	0.000328	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—KRAS—rectum cancer	2.72e-05	0.000328	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB2—HRAS—rectum cancer	2.71e-05	0.000326	CbGpPWpGaD
Sorafenib—RAF1—DAP12 signaling—HRAS—rectum cancer	2.7e-05	0.000325	CbGpPWpGaD
Sorafenib—PDGFRB—Focal Adhesion—HRAS—rectum cancer	2.69e-05	0.000324	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—KRAS—rectum cancer	2.67e-05	0.000322	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—NRAS—rectum cancer	2.67e-05	0.000322	CbGpPWpGaD
Sorafenib—KDR—Axon guidance—HRAS—rectum cancer	2.65e-05	0.00032	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—NRAS—rectum cancer	2.65e-05	0.000319	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	2.64e-05	0.000318	CbGpPWpGaD
Sorafenib—PDGFRB—B Cell Activation—HRAS—rectum cancer	2.63e-05	0.000317	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—NRAS—rectum cancer	2.59e-05	0.000312	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—rectum cancer	2.56e-05	0.000309	CbGpPWpGaD
Sorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	2.55e-05	0.000308	CbGpPWpGaD
Sorafenib—BRAF—Neuronal System—HRAS—rectum cancer	2.55e-05	0.000307	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—KRAS—rectum cancer	2.54e-05	0.000306	CbGpPWpGaD
Sorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	2.54e-05	0.000306	CbGpPWpGaD
Sorafenib—RAF1—DAP12 interactions—HRAS—rectum cancer	2.54e-05	0.000306	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR in disease—HRAS—rectum cancer	2.54e-05	0.000306	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—KRAS—rectum cancer	2.53e-05	0.000305	CbGpPWpGaD
Sorafenib—MAPK11—Signaling by NGF—HRAS—rectum cancer	2.52e-05	0.000304	CbGpPWpGaD
Sorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	2.52e-05	0.000304	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR—HRAS—rectum cancer	2.51e-05	0.000303	CbGpPWpGaD
Sorafenib—BRAF—Signaling by NGF—HRAS—rectum cancer	2.5e-05	0.000301	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	2.49e-05	0.000301	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR in Cancer—HRAS—rectum cancer	2.49e-05	0.0003	CbGpPWpGaD
Sorafenib—RAF1—Signaling by PDGF—HRAS—rectum cancer	2.48e-05	0.000299	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—NRAS—rectum cancer	2.4e-05	0.000289	CbGpPWpGaD
Sorafenib—RAF1—Focal Adhesion—HRAS—rectum cancer	2.4e-05	0.000289	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—NRAS—rectum cancer	2.36e-05	0.000285	CbGpPWpGaD
Sorafenib—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	2.32e-05	0.00028	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HRAS—rectum cancer	2.31e-05	0.000279	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—HRAS—rectum cancer	2.3e-05	0.000277	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—KRAS—rectum cancer	2.3e-05	0.000277	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—KRAS—rectum cancer	2.28e-05	0.000275	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—HRAS—rectum cancer	2.27e-05	0.000274	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	2.25e-05	0.000271	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—KRAS—rectum cancer	2.23e-05	0.000268	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—NRAS—rectum cancer	2.22e-05	0.000268	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	2.2e-05	0.000266	CbGpPWpGaD
Sorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	2.17e-05	0.000262	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—HRAS—rectum cancer	2.16e-05	0.00026	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—TP53—rectum cancer	2.16e-05	0.00026	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—HRAS—rectum cancer	2.15e-05	0.000259	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—NRAS—rectum cancer	2.14e-05	0.000258	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—KRAS—rectum cancer	2.07e-05	0.000249	CbGpPWpGaD
Sorafenib—MKNK1—Disease—NRAS—rectum cancer	2.05e-05	0.000247	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—KRAS—rectum cancer	2.03e-05	0.000245	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—NRAS—rectum cancer	1.97e-05	0.000237	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—HRAS—rectum cancer	1.95e-05	0.000235	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—HRAS—rectum cancer	1.94e-05	0.000234	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—KRAS—rectum cancer	1.92e-05	0.000231	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—NRAS—rectum cancer	1.9e-05	0.000229	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—HRAS—rectum cancer	1.89e-05	0.000228	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	1.87e-05	0.000226	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—KRAS—rectum cancer	1.84e-05	0.000222	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—NRAS—rectum cancer	1.78e-05	0.000214	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—NRAS—rectum cancer	1.77e-05	0.000214	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—NRAS—rectum cancer	1.77e-05	0.000214	CbGpPWpGaD
Sorafenib—MKNK1—Disease—KRAS—rectum cancer	1.77e-05	0.000213	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—HRAS—rectum cancer	1.76e-05	0.000212	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—NRAS—rectum cancer	1.76e-05	0.000212	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HRAS—rectum cancer	1.76e-05	0.000212	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—NRAS—rectum cancer	1.73e-05	0.000209	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—HRAS—rectum cancer	1.73e-05	0.000208	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—NRAS—rectum cancer	1.7e-05	0.000205	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—NRAS—rectum cancer	1.7e-05	0.000205	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—KRAS—rectum cancer	1.69e-05	0.000204	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—NRAS—rectum cancer	1.68e-05	0.000203	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—NRAS—rectum cancer	1.68e-05	0.000202	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—KRAS—rectum cancer	1.64e-05	0.000197	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—HRAS—rectum cancer	1.63e-05	0.000196	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—NRAS—rectum cancer	1.61e-05	0.000195	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—NRAS—rectum cancer	1.61e-05	0.000194	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—HRAS—rectum cancer	1.56e-05	0.000188	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—KRAS—rectum cancer	1.53e-05	0.000185	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—KRAS—rectum cancer	1.53e-05	0.000184	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—KRAS—rectum cancer	1.53e-05	0.000184	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—NRAS—rectum cancer	1.52e-05	0.000184	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—KRAS—rectum cancer	1.52e-05	0.000183	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—NRAS—rectum cancer	1.51e-05	0.000182	CbGpPWpGaD
Sorafenib—MKNK1—Disease—HRAS—rectum cancer	1.5e-05	0.000181	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—NRAS—rectum cancer	1.5e-05	0.00018	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—KRAS—rectum cancer	1.49e-05	0.00018	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—KRAS—rectum cancer	1.46e-05	0.000176	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—KRAS—rectum cancer	1.46e-05	0.000176	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—NRAS—rectum cancer	1.45e-05	0.000175	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—KRAS—rectum cancer	1.45e-05	0.000174	CbGpPWpGaD
Sorafenib—CDK7—Disease—NRAS—rectum cancer	1.45e-05	0.000174	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—KRAS—rectum cancer	1.44e-05	0.000174	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—TYMS—rectum cancer	1.44e-05	0.000173	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—TYMS—rectum cancer	1.44e-05	0.000173	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—HRAS—rectum cancer	1.44e-05	0.000173	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—NRAS—rectum cancer	1.44e-05	0.000173	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—HRAS—rectum cancer	1.39e-05	0.000168	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—KRAS—rectum cancer	1.39e-05	0.000167	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—KRAS—rectum cancer	1.39e-05	0.000167	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—rectum cancer	1.36e-05	0.000164	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—rectum cancer	1.35e-05	0.000162	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—NRAS—rectum cancer	1.35e-05	0.000162	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—rectum cancer	1.33e-05	0.00016	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	1.32e-05	0.00016	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—KRAS—rectum cancer	1.31e-05	0.000158	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—HRAS—rectum cancer	1.3e-05	0.000157	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—KRAS—rectum cancer	1.3e-05	0.000157	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HRAS—rectum cancer	1.3e-05	0.000156	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HRAS—rectum cancer	1.3e-05	0.000156	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NRAS—rectum cancer	1.29e-05	0.000156	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—NRAS—rectum cancer	1.29e-05	0.000156	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—HRAS—rectum cancer	1.29e-05	0.000155	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—KRAS—rectum cancer	1.29e-05	0.000155	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—HRAS—rectum cancer	1.27e-05	0.000153	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	1.25e-05	0.00015	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HRAS—rectum cancer	1.24e-05	0.00015	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HRAS—rectum cancer	1.24e-05	0.00015	CbGpPWpGaD
Sorafenib—CDK7—Disease—KRAS—rectum cancer	1.24e-05	0.00015	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—KRAS—rectum cancer	1.24e-05	0.000149	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HRAS—rectum cancer	1.23e-05	0.000148	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HRAS—rectum cancer	1.23e-05	0.000148	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—TYMS—rectum cancer	1.22e-05	0.000147	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—TYMS—rectum cancer	1.21e-05	0.000146	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HRAS—rectum cancer	1.18e-05	0.000142	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HRAS—rectum cancer	1.18e-05	0.000142	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	1.18e-05	0.000142	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KRAS—rectum cancer	1.16e-05	0.00014	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NRAS—rectum cancer	1.14e-05	0.000138	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—rectum cancer	1.14e-05	0.000138	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—HRAS—rectum cancer	1.12e-05	0.000134	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KRAS—rectum cancer	1.11e-05	0.000134	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KRAS—rectum cancer	1.11e-05	0.000134	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HRAS—rectum cancer	1.11e-05	0.000133	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—rectum cancer	1.1e-05	0.000132	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—rectum cancer	1.09e-05	0.000132	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	1.06e-05	0.000128	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—rectum cancer	1.06e-05	0.000127	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—rectum cancer	1.05e-05	0.000127	CbGpPWpGaD
Sorafenib—BRAF—Disease—NRAS—rectum cancer	1.05e-05	0.000126	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NRAS—rectum cancer	1.03e-05	0.000124	CbGpPWpGaD
Sorafenib—KIT—Immune System—NRAS—rectum cancer	1.03e-05	0.000124	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—rectum cancer	9.89e-06	0.000119	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—rectum cancer	9.85e-06	0.000119	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KRAS—rectum cancer	9.85e-06	0.000119	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—rectum cancer	9.79e-06	0.000118	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—rectum cancer	9.77e-06	0.000118	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—rectum cancer	9.53e-06	0.000115	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—rectum cancer	9.46e-06	0.000114	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—rectum cancer	9.46e-06	0.000114	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—rectum cancer	9.19e-06	0.000111	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—rectum cancer	9.04e-06	0.000109	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—rectum cancer	9.02e-06	0.000109	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—rectum cancer	9.01e-06	0.000109	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TYMS—rectum cancer	8.94e-06	0.000108	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—rectum cancer	8.88e-06	0.000107	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—rectum cancer	8.88e-06	0.000107	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—rectum cancer	8.83e-06	0.000106	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—rectum cancer	8.8e-06	0.000106	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TYMS—rectum cancer	8.74e-06	0.000105	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—rectum cancer	8.61e-06	0.000104	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—rectum cancer	8.59e-06	0.000103	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—rectum cancer	8.43e-06	0.000102	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—rectum cancer	8.41e-06	0.000101	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—rectum cancer	8.37e-06	0.000101	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—rectum cancer	8.2e-06	9.88e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—rectum cancer	8.13e-06	9.79e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—rectum cancer	7.91e-06	9.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—rectum cancer	7.84e-06	9.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—rectum cancer	7.78e-06	9.38e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—rectum cancer	7.76e-06	9.35e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—rectum cancer	7.66e-06	9.23e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—rectum cancer	7.6e-06	9.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—rectum cancer	7.57e-06	9.13e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TYMS—rectum cancer	7.57e-06	9.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—rectum cancer	7.55e-06	9.1e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—rectum cancer	7.55e-06	9.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—rectum cancer	7.41e-06	8.93e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—rectum cancer	7.41e-06	8.93e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—rectum cancer	7.4e-06	8.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—rectum cancer	7.39e-06	8.9e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—rectum cancer	7.33e-06	8.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—rectum cancer	7.24e-06	8.73e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—rectum cancer	7.17e-06	8.63e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—rectum cancer	7.15e-06	8.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—rectum cancer	6.99e-06	8.43e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—rectum cancer	6.97e-06	8.4e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TYMS—rectum cancer	6.76e-06	8.14e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—rectum cancer	6.75e-06	8.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—rectum cancer	6.75e-06	8.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—rectum cancer	6.72e-06	8.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—rectum cancer	6.67e-06	8.04e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—rectum cancer	6.67e-06	8.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—rectum cancer	6.62e-06	7.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—rectum cancer	6.6e-06	7.95e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TYMS—rectum cancer	6.6e-06	7.95e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—rectum cancer	6.58e-06	7.93e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—rectum cancer	6.46e-06	7.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—rectum cancer	6.44e-06	7.76e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—rectum cancer	6.38e-06	7.69e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—rectum cancer	6.37e-06	7.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—rectum cancer	6.33e-06	7.63e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—rectum cancer	6.32e-06	7.61e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—rectum cancer	6.31e-06	7.6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—rectum cancer	6.3e-06	7.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—rectum cancer	6.28e-06	7.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—rectum cancer	6.23e-06	7.51e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—rectum cancer	6.22e-06	7.49e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—rectum cancer	6.16e-06	7.43e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—rectum cancer	5.94e-06	7.16e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—rectum cancer	5.74e-06	6.92e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—rectum cancer	5.74e-06	6.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—rectum cancer	5.74e-06	6.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	5.69e-06	6.86e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—rectum cancer	5.66e-06	6.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—rectum cancer	5.61e-06	6.76e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—rectum cancer	5.45e-06	6.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—rectum cancer	5.44e-06	6.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—rectum cancer	5.43e-06	6.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—rectum cancer	5.42e-06	6.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—rectum cancer	5.41e-06	6.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—rectum cancer	5.36e-06	6.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—rectum cancer	5.3e-06	6.38e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—rectum cancer	5.27e-06	6.35e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—rectum cancer	5.1e-06	6.15e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—rectum cancer	5.1e-06	6.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—rectum cancer	5.07e-06	6.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	4.9e-06	5.9e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—rectum cancer	4.88e-06	5.88e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—rectum cancer	4.88e-06	5.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—rectum cancer	4.84e-06	5.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—rectum cancer	4.83e-06	5.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—rectum cancer	4.67e-06	5.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—rectum cancer	4.63e-06	5.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—rectum cancer	4.62e-06	5.57e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—rectum cancer	4.38e-06	5.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—rectum cancer	4.37e-06	5.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—rectum cancer	4.35e-06	5.25e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	4.16e-06	5.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—rectum cancer	4.15e-06	5e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—rectum cancer	4.06e-06	4.9e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—rectum cancer	3.97e-06	4.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—rectum cancer	3.88e-06	4.68e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—rectum cancer	3.77e-06	4.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—rectum cancer	3.71e-06	4.47e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—rectum cancer	3.35e-06	4.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—rectum cancer	3.2e-06	3.86e-05	CbGpPWpGaD
